Evidence map›Paper›PMID 41445726›Full record

ReviewFrontiers in immunology2025

Maciej Mazurek, Wojciech Młynarski, Dawid P Grzela

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Maciej MazurekDepartment of Pediatrics, Oncology and Hematology, Medical University of Lodz, Lodz, Poland.
Wojciech MłynarskiDepartment of Pediatrics, Oncology and Hematology, Medical University of Lodz, Lodz, Poland.
Dawid P GrzelaDepartment of Pediatrics, Oncology and Hematology, Medical University of Lodz, Lodz, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

For centuries, hematologists have strived to develop increasingly sophisticated systems and therapeutic protocols for replenishing the blood. However, demographic shifts have led to a growing demand for blood-derived products, and the number of eligible donors continues to decline, raising concerns regarding the future availability and cost-effectiveness of transfusion therapies. Advances in our understanding of molecular hematopoiesis, coupled with the development of precise gene-editing tools such as CRISPR/Cas9 and the advent of induced pluripotent stem cell (iPSCs) technology, have opened new avenues for the generation of functional blood components

Indexed as

Blood PlateletsInduced Pluripotent Stem CellsMegakaryocytesAnimalsCell DifferentiationGene EditingHematopoiesisHumansTranslational Research, Biomedicalcell-based transfusion therapyinduced pluripotent stem cells (iPSCs)in vitro hematopoiesismegakaryocyte differentiationplatelet biogenesis

Identifiers

PMID41445726
PMCPMC12722799

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.